Dr. Kumar on Potential of CAR T-Cell Therapy in Multiple Myeloma

Shaji Kumar, MD
Published: Tuesday, May 02, 2017



Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in the field of multiple myeloma.

The potential of CAR T-cell therapy depends on the results that stem from ongoing clinical trials exploring this type of treatment in these patients, Kumar says. It is too early to speak to the efficacy of CAR T-cell therapy, as well as the immunotherapy agents being studied. Moreover, the toxicity profile has been found to be high in many patients.

Because of the associated toxicities, this may not be the ideal treatment to use in the upfront setting, he adds.
SELECTED
LANGUAGE


Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in the field of multiple myeloma.

The potential of CAR T-cell therapy depends on the results that stem from ongoing clinical trials exploring this type of treatment in these patients, Kumar says. It is too early to speak to the efficacy of CAR T-cell therapy, as well as the immunotherapy agents being studied. Moreover, the toxicity profile has been found to be high in many patients.

Because of the associated toxicities, this may not be the ideal treatment to use in the upfront setting, he adds.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x